Predicting Secukinumab Fast-Responder Profile in Psoriatic Patients: Advanced Application of Artificial-Neural-Networks (ANNs)

December 2020 | Volume 19 | Issue 12 | Editorials | 1241 | Copyright © December 2020


Published online November 4, 2020

Giovanni Damiani MD,a,b,c,d,e Rosalynn R.Z. Conic MD PhD,a Paolo D.M. Pigatto Prof MD,d,e Carlo G. Carrera MD,c Chiara Franchi MD,d Angelo Cattaneo MD,c Piergiorgio Malagoli MD,f Radhakrishna Uppala Prof MD PhD,g Dennis Linder Prof MD,h Nicola L. Bragazzi MD PhD,i Enzo Grossi Prof MDj

aDepartment of Dermatology, Case Western Reserve University, Cleveland, OH
bYoung Dermatologists Italian Network
cUOC Dermatologia, Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, UOC Dermatology, IRCCS Fondazione Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy
dClinical Dermatology, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy
eDepartment of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
fDermatology Unit,Azienda Ospedaliera San Donato Milanese, Milan, Italy
gDepartment of Obstetrics and Gynecology, Oakland University William Beaumont School of Medicine, Royal Oak, MI
hUnit of Dermatology, Ben Gurion University of the Negev, Beer-Sheva, Israel
iSchool of Public Health, Department of Health Sciences (DISSAL), University of Genoa, Italy
jFondazioneVilla Santa Maria,Tavernerio, Como, Italy






smoking >5 years), 3 never-smokers, and 15 smokers with 32 [12–219.5] pack/year index. None of the enrolled patients had positive ANA. DLQI at week 0 was 16.14-18 At week 4, 6 patients achieved PASI > 90 and an additional 13 patients achieved PASI >75.Thus 19 patients were fast-responders and 4 patients’ non-responders.
Close Menu